专利悬崖边缘的替诺福韦酯专利现状  

Review of Patents on Tenefovir and the Forthcoming Patent Cliff

作　　者：王博[1] 韩雅婷 张伟波[1] 

机构地区：[1]国家知识产权局专利局化学发明审查部,北京100088

出　　处：《药学进展》2017年第11期846-851,共6页Progress in Pharmaceutical Sciences

摘　　要：替诺福韦酯作为一种抗病毒药物,是吉利德公司非常成功的明星产品。介绍了吉利德公司关于替诺福韦酯的专利技术情况,总结了其面临专利悬崖时的应对策略。吉利德公司采取了申请复方制剂专利和替代产品专利,同时主动降价的策略,既保证了对仿制药的竞争优势,又提前给其替代产品替诺福韦艾拉酚胺占据了更广阔的市场。吉利德公司采取的专利布局与新药研发紧密结合的策略,非常值得国内药企借鉴。As an antiviral drug, tenefovir dipivoxil is a very successful star product of Gilead. In this paper, we introduced Gilead＇s patented technology of tenefovir, and summarized its countermeasures against the forthcoming patent cliff. By filing a number of patent applications for compound formulations and alternative products as well as offering lower prices, Gilead establishes its competitive advantages over upcoming generics and pre-occupies a bigger market share for tenofovir alafenaimde. Gilead＇s strategy of integrating patent portfolio and new drug development sets a good example for our domestic pharmaceutical companies.

关 键 词：替诺福韦 专利悬崖 原研 复方制剂 

分 类 号：G306[文化科学] R978.7[医药卫生—药品]